Answers are grounded in this paper and cite their sources.
Background: When it comes to developing new cancer diagnostics (Dx) and therapeutics (Rx), time is of the essence-for the patients that need treatments most, every day counts. Traditional benchmarks of Dx and Rx have delivered favorable clinical outcomes on a slower timeline than patients can afford.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: